Item 2.02 Results of Operations and Financial Condition.

On May 12, 2022, Day One Biopharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this report.

Item 7.01 Regulation FD Disclosure.

On May 12, 2022, Day One Biopharmaceuticals, Inc. updated its corporate presentation. A copy of the updated presentation is attached as Exhibit 99.2 to this report.

The information in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 to this report, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Current Report on Form 8-K and in the accompanying Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits




Exhibit                                   Description
Number

99.1          Press release issued by Day One Biopharmaceuticals, Inc. regarding its
            financial results for the quarter ended March 31, 2022, dated May 12,
            2022.

99.2          Corporate Presentation

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses